EntryPoint Capital’s Emergent Biosolutions EBS Stock Holding History

EntryPoint Capital’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$121K	Buy	+14,577	New	+$151K	0.04%	692
2025 Q3	–	Sell	-43,220	Closed	-$276K	–	729
2025 Q2	$276K	Buy	+43,220	New	+$247K	0.14%	323
2024 Q4	–	Sell	-20,980	Closed	-$175K	–	790
2024 Q3	$175K	Buy	+20,980	New	+$191K	0.1%	498

Other funds holding EBS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PCM

Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

EntryPoint Capital's EBS Position: Q1 2026 in Review

EntryPoint Capital opened a new position in Emergent Biosolutions (EBS) in Q1 2026: 14,577 shares worth $121K. The stake represents 0.04% of the portfolio and ranks #692 among its holdings. This is a return to the name: EntryPoint Capital previously reported a position in EBS as recently as Q2 2025.

EntryPoint Capital first reported a position in EBS in Q3 2024 and has held it in 3 quarters since. The position peaked at $276K in Q2 2025. 190 funds tracked by Wall St. Rank hold EBS as of Q1 2026.

EntryPoint Capital held 14,577 shares of Emergent Biosolutions worth $121K as of Q1 2026.
Emergent Biosolutions was a new EntryPoint Capital position in Q1 2026.
Emergent Biosolutions made up 0.04% of EntryPoint Capital's portfolio in Q1 2026, its #692 holding.
EntryPoint Capital first reported a position in Emergent Biosolutions in Q3 2024 and has held it in 3 quarters since.
EntryPoint Capital's Emergent Biosolutions position peaked at $276K in Q2 2025.
190 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q1 2026.

Based on EntryPoint Capital's 13F filing for Q1 2026, filed 14 May 2026.